August 07, 2023
A New York federal judge has confirmed a nearly $16.6 million arbitral award issued to Acorda Therapeutics Inc. in its dispute with Alkermes PLC over a multiple sclerosis drug, but refused to increase the award by $65.6 million to refund the company for royalties paid after the drug's patent expired.
January 11, 2023
Acorda Therapeutics Inc. has told a New York federal court that an arbitral tribunal got it wrong when it awarded the company only $16 million in a royalties dispute with an Irish pharmaceutical company, saying it's owed an additional $65 million.